Rezolute Inc. (RZLT)

[Whalatane]

Well the available research certainly doesn't line up with RZLT mgt / advisors view on importance of CSTClinical Significance of CST Reduction

A post-hoc analysis of the Protocol T trial showed that changes in CST accounted for only a small proportion of the total variation in changes in visual acuity with anti-VEGF treatment for DME.
While anti-VEGF therapy led to reductions in CST, the magnitude of vision improvement was not strongly associated with the degree of anatomic CST change.
Factors like baseline hemoglobin A1c levels were more strongly associated with the extent of visual acuity gains than changes in CST.
The presence of intraretinal cystic spaces was associated with greater CST reductions after a meal challenge, but the clinical relevance of these short-term CST fluctuations is unclear.
Overall, the studies indicate that CST is an imperfect surrogate for visual function, and reductions in CST do not reliably predict proportional improvements in visual acuity outcomes for DME patients.
In summary, while anti-VEGF therapies can reduce CST in DME, the clinical significance of these CST reductions in terms of direct visual acuity benefits appears to be limited.
CST changes alone should not be used as a surrogate for predicted vision gains.
Other factors beyond CST appear to play a larger role in determining visual outcomes. lowering

From the original PR

“The results are monumental for the DME community,” said Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, Professor of Ophthalmology at the Byers Eye Institute, and Professor of Medicine and Professor of Pediatrics at the Stanford University School of Medicine, and a member of Rezolute’s Scientific Advisory Board. “I am impressed by the significant reduction in CST in this study across all three dosages as retinal thickness is the key biomarker to determine whether a therapy may offer a potential benefit to patients.

Kiwi